📰 Laboratory Abnormalities News
Laboratory Abnormalities News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Laboratory Abnormalities. Real-time updates on events, politics, business and more.
May 23, 2024
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2024
Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients for Psoriasis Area and Severity Index 75 in the POETYK PSO long-term...
January 24, 2024
/PRNewswire/ -- Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this years ASCO GU Symposium...
December 16, 2023
PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #CRC--Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients whose disease has progres...
December 15, 2023
Bristol Myers Squibb today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable metastatic...
December 12, 2023
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a...
December 1, 2023
The first and only non-covalent BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least...
November 2, 2023
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Brutons tyrosine kinase...
October 12, 2023
Clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment in the POETYK PSO long-term extension trialSotyktu demonstrated a consistent safety profile with no increases in adverse events or serious adverse events and no emergence of any...
October 12, 2023
First presentation of results from CheckMate -901 show survival benefit with Opdivo + chemotherapy in the first-line treatment of patients with unresectable or metastatic urothelial carcinoma who...